CommercialCoverageMedium impact
08.02.35, Drugs, Biologics, or Gene Therapies with an Accelerated Approval
Independence Blue Cross·Oncology, Rheumatology, Neurology +6 more·Pharmacy
Effective date
Jan 1, 2025
We identified it
Jun 19, 2026
Summary
A new commercial policy has been implemented covering drugs, biologics, or gene therapies with accelerated FDA approval. This policy establishes coverage guidelines and likely prior authorization requirements for these accelerated approval treatments effective January 1, 2025.
Action Required
By January 1, 2025: Billing team must review the full policy details at the provided URL to understand specific coverage criteria and prior authorization requirements for drugs, biologics, and gene therapies with accelerated FDA approval. Update billing workflows to verify coverage and obtain required authorizations before administering these treatments. Monitor for claim denials if proper authorization processes are not followed.